Search

Search results

1498 results found

Head injury, α-synuclein Rep1, and Parkinson's disease. Ann Neurol 2012;71:40-8.

Publication: Journal Article

Goldman, SM, F Kamel, GW Ross, SA Jewell, GS Bhudhikanok, D Umbach, C Marras, et al. 2012. “Head Injury, α-Synuclein Rep1, and Parkinson’s Disease. Ann Neurol 2012;71:40-8.”. Ann Neurol.

Pramipexole ER Study Group. Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: a double-blind, randomized trial. Clin Neuropharmacol 2012;35:174-81.

Publication: Journal Article

Mizuno, Y, M Yamamoto, S Kuno, K Hasegawa, N Hattori, T Kagimura, A Sarashina, et al. 2012. “Pramipexole ER Study Group. Efficacy and Safety of Extended- versus Immediate-Release Pramipexole in Japanese Patients With Advanced and L-Dopa-Undertreated Parkinson Disease: A Double-Blind, Randomized Trial. Clin Neuropharmacol 2012;35:174-81.”. Clin Neuropharmacol.

Determination of Minimal Clinically Important Change in Early and Advanced Parkinson's Disease. Mov Disord 2011;26:813-8.

Publication: Journal Article

Hauser, RA, P Auinger, and Parkinson Study Group. 2011. “Determination of Minimal Clinically Important Change in Early and Advanced Parkinson’s Disease. Mov Disord 2011;26:813-8.”. Mov Disord.

Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov 2018;17:804-822.

Publication: Journal Article

Charvin, D, R Medori, RA Hauser, and O Rascol. 2018. “Therapeutic Strategies for Parkinson Disease: Beyond Dopaminergic Drugs. Nat Rev Drug Discov 2018;17:804-822.”. Nat Rev Drug Discov.

AQUASS Welcomes Lab Manager and Social and Behavioral Researcher Yiwen Zha, MEd

News: September 06, 2024

The AQASS Research Lab is pleased to announce the appointment of Ms. Yiwen Zha as Social and Behavioral Researcher and Lab Manager. A double Master's degree graduate of Vanderbilt University and Harvard University, Ms. Zha joins us with a robust background in educational research. As Lab Manager, Ms...

Ali Karimi

Person: Medical Student

Ali is a third-year medical student with a deep passion for the brain's complexity. This interest led to involvement in cognitive science and neurology research as an undergraduate, further fueling the desire to specialize in neurology. Outside medicine, Ali enjoys audiobooks on history, economics...

Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease

Publication: Journal Article

Hauser, RA, J Bronzova, C Sampaio, AE Lang, O Rascol, A Theeuwes, and SV Van De Witte. 2009. “Safety and Tolerability of Pardoprunox, a New Partial Dopamine Agonist, in a Randomized, Controlled Study of Patients With Advanced Parkinson’s Disease”. Eur Neurol.

Search

Search results

Head injury, α-synuclein Rep1, and Parkinson's disease. Ann Neurol 2012;71:40-8.

Pramipexole ER Study Group. Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: a double-blind, randomized trial. Clin Neuropharmacol 2012;35:174-81.

Determination of Minimal Clinically Important Change in Early and Advanced Parkinson's Disease. Mov Disord 2011;26:813-8.

Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov 2018;17:804-822.

AQUASS Welcomes Lab Manager and Social and Behavioral Researcher Yiwen Zha, MEd

Ali Karimi

KETAMINE: Neural-and network-level changes

Future treatments for Parkinson’s disease: surfing the PD pipeline

Neural transplants in patients with Huntington’s disease undergo disease-like neuronal degeneration.

Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease